Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology…
Month: September 2023
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology…
Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today…
Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today…
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program
– 850 cancer cell lines screened in Broad Institute’s PRISM lab – – Rencofilstat active…
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program
– 850 cancer cell lines screened in Broad Institute’s PRISM lab – – Rencofilstat active…
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari”…
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari”…
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Bluejay Therapeutics, Inc. a private clinical…
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development
SAN MATEO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Bluejay Therapeutics, Inc. a private clinical…
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to…
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to…
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
– Phase 2a NASH protocol on track to be submitted to the IND in Q4…
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
– Phase 2a NASH protocol on track to be submitted to the IND in Q4…
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
– New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support…
Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
– New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support…
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2…
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2…